Horizon Therapeutics PLC (HZNP): Price and Financial Metrics
HZNP Price/Volume Stats
|Current price||$116.30||52-week high||$116.38|
|Prev. close||$116.25||52-week low||$60.03|
|Day high||$116.38||Avg. volume||2,498,525|
|50-day MA||$109.80||Dividend yield||N/A|
|200-day MA||$108.24||Market Cap||26.63B|
HZNP Stock Price Chart Interactive Chart >
HZNP POWR Grades
- HZNP scores best on the Growth dimension, with a Growth rank ahead of 89.62% of US stocks.
- HZNP's strongest trending metric is Stability; it's been moving down over the last 49 days.
- HZNP's current lowest rank is in the Momentum metric (where it is better than 15.18% of US stocks).
HZNP Stock Summary
- HORIZON THERAPEUTICS PUBLIC LTD CO's market capitalization of $26,620,618,530 is ahead of 92.11% of US-listed equities.
- HZNP's current price/earnings ratio is 60.78, which is higher than 90.92% of US stocks with positive earnings.
- In terms of volatility of its share price, HZNP is more volatile than just 5.8% of stocks we're observing.
- Stocks that are quantitatively similar to HZNP, based on their financial statements, market capitalization, and price volatility, are AZPN, A, RMD, LOGI, and OSIS.
- HZNP's SEC filings can be seen here. And to visit HORIZON THERAPEUTICS PUBLIC LTD CO's official web site, go to www.horizontherapeutics.com.
HZNP Valuation Summary
- HZNP's price/sales ratio is 7.3; this is 305.56% higher than that of the median Healthcare stock.
- Over the past 148 months, HZNP's price/sales ratio has gone down 38.2.
Below are key valuation metrics over time for HZNP.
HZNP Growth Metrics
- Its 2 year price growth rate is now at 124.58%.
- Its 4 year revenue growth rate is now at 37.93%.
- Its 3 year net cashflow from operations growth rate is now at 302.79%.
The table below shows HZNP's growth in key financial areas (numbers in millions of US dollars).
|Date||Revenue||Operating Cash Flow||Net Income to Common Stock|
HZNP's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- HZNP has a Quality Grade of C, ranking ahead of 61.77% of graded US stocks.
- HZNP's asset turnover comes in at 0.385 -- ranking 123rd of 681 Pharmaceutical Products stocks.
- VNDA, NEOG, and CEMI are the stocks whose asset turnover ratios are most correlated with HZNP.
The table below shows HZNP's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
Horizon Therapeutics PLC (HZNP) Company Bio
Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (Source:Wikipedia)
HZNP Latest News Stream
|Loading, please wait...|
HZNP Latest Social Stream
View Full HZNP Social Stream
Latest HZNP News From Around the Web
Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
DUBLIN, October 06, 2023-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
DUBLIN, October 03, 2023--IRISH TAKEOVER PANEL
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
DUBLIN, October 02, 2023--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2023.
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
DUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023.
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
DUBLIN, September 26, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing.
HZNP Price Returns
Continue Researching HZNPWant to do more research on Horizon Therapeutics Public Ltd Co's stock and its price? Try the links below:
Horizon Therapeutics Public Ltd Co (HZNP) Stock Price | Nasdaq
Horizon Therapeutics Public Ltd Co (HZNP) Stock Quote, History and News - Yahoo Finance
Horizon Therapeutics Public Ltd Co (HZNP) Stock Price and Basic Information | MarketWatch